Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease
Public ClinicalTrials.gov record NCT00816660. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex (rVWF:rFVIII): A Phase 1 Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability in Type 3 Von Willebrand Disease (VWD)
Study identification
- NCT ID
- NCT00816660
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Interventions
- Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII) Biological
- Marketed plasma-derived VWF/FVIII concentrate Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2008
- Primary completion
- Aug 30, 2010
- Completion
- Aug 30, 2010
- Last update posted
- May 2, 2021
2008 – 2010
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Emory University School of Medicine, Dept. of Pediatrics | Atlanta | Georgia | 30092 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Indiana Hemophilia and Thrombosis Center | Indianapolis | Indiana | 46260 | — |
| University of Kentucky Hemophilia Treatment Center | Lexington | Kentucky | 40536-0284 | — |
| Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Brigham & Women´s Hospital, Hematology Division | Boston | Massachusetts | 02115 | — |
| Rochester General Hospital | Rochester | New York | 14621 | — |
| Hemophilia Center of Western PA | Pittsburgh | Pennsylvania | 15213-4306 | — |
| University of Texas | Houston | Texas | 77030 | — |
| Comprehensive Center for Bleeding Disorders | Milwaukee | Wisconsin | 53225-3548 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00816660, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 2, 2021 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00816660 live on ClinicalTrials.gov.